The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Immunohistochemical (IHC) prediction of lapatinib efficacy in HER2-positive advanced breast cancer patients.
Renata Duchnowska
No relevant relationships to disclose
Piotr Jan Wysocki
No relevant relationships to disclose
Konstanty Korski
No relevant relationships to disclose
Bogumila Czartoryska-Arlukowicz
No relevant relationships to disclose
Anna Niwinska
No relevant relationships to disclose
Marlena Orlikowska
No relevant relationships to disclose
Barbara Radecka
No relevant relationships to disclose
Maciej Studziński
No relevant relationships to disclose
Regina Demlova
No relevant relationships to disclose
Barbara Ziolkowska
No relevant relationships to disclose
Monika Merdalska
No relevant relationships to disclose
Lukasz Hajac
No relevant relationships to disclose
Paulina Myśliwiec
No relevant relationships to disclose
Dorota Zuziak
No relevant relationships to disclose
Sylwia Debska
No relevant relationships to disclose
Istvan Lang
No relevant relationships to disclose
Malgorzata Foszczynska-Kloda
No relevant relationships to disclose
Anna Kowalczyk
No relevant relationships to disclose
Wojciech Biernat
No relevant relationships to disclose
Jacek Jassem
No relevant relationships to disclose